| 1 |
Jiang W, Wu DB, Fu SY, Chen EQ, Tang H, Zhou TY. Insight into the role of TRAIL in liver diseases. Biomed Pharmacother 2019;110:641-5. [PMID: 30544063 DOI: 10.1016/j.biopha.2018.12.004] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 2 |
Wang L, Min Z, Wang X, Hu M, Song D, Ren Z, Cheng Y, Wang Y. Arsenic trioxide and sorafenib combination therapy for human hepatocellular carcinoma functions via up-regulation of TNF-related apoptosis-inducing ligand. Oncol Lett 2018;16:3341-50. [PMID: 30127933 DOI: 10.3892/ol.2018.8981] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 3 |
Zhong HH, Wang HY, Li J, Huang YZ. TRAIL-based gene delivery and therapeutic strategies. Acta Pharmacol Sin 2019;40:1373-85. [PMID: 31444476 DOI: 10.1038/s41401-019-0287-8] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 7.0] [Reference Citation Analysis]
|
| 4 |
Gibriel AA, Ismail MF, Sleem H, Zayed N, Yosry A, El-nahaas SM, Shehata NI. Diagnosis and staging of HCV associated fibrosis, cirrhosis and hepatocellular carcinoma with target identification for miR-650, 552-3p, 676-3p, 512-5p and 147b. CBM 2022. [DOI: 10.3233/cbm-210456] [Reference Citation Analysis]
|
| 5 |
Jiang R, Zhang Z, Liao X, Huang L, Liao Y, Deng W. Combination of oncolytic adenovirus ZD55 harboring TRAIL-IETD-MnSOD and cytokine-induced killer cells against lung cancer. Ann Transl Med 2021;9:1527. [PMID: 34790733 DOI: 10.21037/atm-21-4479] [Reference Citation Analysis]
|
| 6 |
Ma T, Guo R, Wang X, Shen WT, Zhu M, Jin YN, Xu HP. Lentiviral vector with a radiation-inducible promoter, carrying the ING4 gene, mediates radiosensitization controlled by radiotherapy in cervical cancer cells. Oncol Lett 2021;21:67. [PMID: 33365078 DOI: 10.3892/ol.2020.12328] [Reference Citation Analysis]
|
| 7 |
Azemin WA, Alias N, Ali AM, Shamsir MS. In silico analysis prediction of HepTH1-5 as a potential therapeutic agent by targeting tumour suppressor protein networks. J Biomol Struct Dyn 2021;:1-27. [PMID: 34935583 DOI: 10.1080/07391102.2021.2017349] [Reference Citation Analysis]
|
| 8 |
Zhang H, Rao F, Chen Z, Wang Y, Li Y. MicroRNA-34a and E4orf4 synergistically promote apoptosis in Hela cells. Biotechnology & Biotechnological Equipment 2019;33:1419-23. [DOI: 10.1080/13102818.2019.1673206] [Reference Citation Analysis]
|
| 9 |
Diaz Arguello OA, Haisma HJ. Apoptosis-Inducing TNF Superfamily Ligands for Cancer Therapy. Cancers (Basel) 2021;13:1543. [PMID: 33801589 DOI: 10.3390/cancers13071543] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 10 |
Senekal NS, Mahasa KJ, Eladdadi A, de Pillis L, Ouifki R. Natural Killer Cells Recruitment in Oncolytic Virotherapy: A Mathematical Model. Bull Math Biol 2021;83:75. [PMID: 34008149 DOI: 10.1007/s11538-021-00903-6] [Reference Citation Analysis]
|
| 11 |
Shatnawi A, Abu Rabe DI, Frigo DE. Roles of the tumor suppressor inhibitor of growth family member 4 (ING4) in cancer. Adv Cancer Res 2021;152:225-62. [PMID: 34353439 DOI: 10.1016/bs.acr.2021.05.004] [Reference Citation Analysis]
|
| 12 |
Redd Bowman KE, Lu P, Vander Mause ER, Lim CS. Advances in delivery vectors for gene therapy in liver cancer. Therapeutic Delivery 2020;11:833-50. [DOI: 10.4155/tde-2019-0076] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
|
| 13 |
Du Y, Cheng Y, Su G. The essential role of tumor suppressor gene ING4 in various human cancers and non-neoplastic disorders. Biosci Rep 2019;39:BSR20180773. [PMID: 30643005 DOI: 10.1042/BSR20180773] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
|
| 14 |
Thapa B, Kc R, Uludağ H. TRAIL therapy and prospective developments for cancer treatment. J Control Release 2020;326:335-49. [PMID: 32682900 DOI: 10.1016/j.jconrel.2020.07.013] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
|
